[Antiviral effect of recombinant antibody to influenza virus HA antigen].
OBJECTIVE
Study on the antiviral effect in vivo and in vitro of recombinant antibodies with neutralization activity to influenza virus HA antigen, IgG-IV-2 and IgG-IV-6 obtained from expression in Baculo/insert system.


METHODS
Viral titer of influenza virus in MDCK was compared before and after antibody application, and measured viral titer in mouse lung before and after antibodies applied on mucous membrane.


RESULTS
IgG-IV-2 and IgG-IV-6 could reduce the titer from 4.5 log10 TCID50 to half is by 50% at doses 0.8 microg and 0.5 microg respectively. When recombinant antibodies were used on mucous membrane, the IgG-IV-2 and IgG-IV-6 reduced the titer by half at doses 0.25 mg/kg weight and 0.1 mg/kg weight respectively. The dose was 0.08 mg/kg weight when the two antibodies were jointly used.


CONCLUSIONS
The recombinant antibodies have antiviral effect in vivo and in vitro, they can neutralize viral virulence.
Yang
Guibin
G
State Key Lab for Molecular Virology and Genetic Engineering, Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052, China.
Wang
Yan
Y
Zhao
Xiaodong
X
Han
Feng
F
Wu
Shuhua
S
Hou
Yunde
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D000918:Antibody Specificity; D000956:Antigens, Viral / Q000276:immunology; D002460:Cell Line; D009980:Influenza A virus / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral